Building on clinical trial and laboratory research insights from the past decade, the ITN has focused and deliberate strategies to achieving tolerance in each disease area. The research supported by the ITN has unlocked new therapeutic approaches and discovered new biomarkers that promise to change the way physicians treat patients. Explore ITN clinical trials below by using a search term or by sorting the specific trial categories. If you have questions or want more information about ITN clinical trials, contact us.
Principal Investigator:
Sandy Feng | University of California San Francisco | San Francisco, CA
Category:
Transplantation
|
Specific Category:
Liver Transplantation
|
Status:
Complete
Learn more:
(
ITN524ST-CTOT-12
|
ARTIST
)
Principal Investigator:
Kenneth Newell | Emory Healthcare | Atlanta, GA
Larry Turka | Immune Tolerance Network | Boston, MA
Anil Chandraker | | Boston, MA
Category:
Transplantation
|
Specific Category:
Kidney Transplantation
|
Status:
Complete
Learn more:
(
ITN507ST
|
FACTOR
)
Principal Investigator:
Kenneth Newell | Emory Healthcare | Atlanta, GA
Category:
Transplantation
|
Specific Category:
Kidney Transplantation
|
Status:
Complete
Learn more:
(
ITN101ST
|
EVEREST
)
Principal Investigator:
Sandy Feng | | San Francisco, CA
Category:
Transplantation
|
Specific Category:
Liver Transplantation
|
Status:
Enrollment
Learn more:
(
ITN100ST
|
PEARL
)
Principal Investigator:
James Markmann | University of Pennsylvania | Philadelphia, PA
Category:
Transplantation
|
Specific Category:
Liver Transplantation
|
Status:
Closed
Learn more:
(
ITN095AI
|
DESIGNATE
)
Principal Investigator:
Stephen Gitelman | University of California San Francisco | San Francisco, CA
DESIGNATE is a clinical study to identify a safe, metabolically favorable, dosing regimen for siplizumab in patients with type 1 diabetes mellitus.
Category:
Type 1 Diabetes
|
Specific Category:
New Onset Type 1 Diabetes
|
Status:
Analysis
Learn more:
(
ITN093AI
|
DARE-APS
)
Principal Investigator:
Doruk Erkan | Hospital for Special Surgery | New York, NY
Jason Knight | University of Michigan | Ann Arbor, MI
A study about the safety of daratumumab in patients with antiphospholipid syndrome (APS), and its effectiveness at reducing the antiphospholipid antibodies that cause APS.
Category:
Autoimmune Disease
|
Specific Category:
Primary Antiphospholipid Syndrome
|
Status:
Enrollment
Learn more:
(
ITN092AI
|
CONTROL-RA
)
Principal Investigator:
Bill St. Clair | Duke University | Durham, NC
The goal of CONTROL-RA is to see how the experimental study drug, VIB4920, affects control of rheumatoid arthritis (RA).
Category:
Autoimmune Disease
|
Specific Category:
Autoimmune Diseases
|
Status:
Closed
Learn more:
(
ITN091AI
|
VIBRANT
)
Principal Investigator:
Maria Dall'era | University of California San Francisco | San Francisco, CA
Betty Diamond | The Feinstein Institute for Medical Research | Manhasset, NY
David Wofsy | University of California San Francisco | San Francisco, CA
The goal of the VIBRANT trial is to determine if treating lupus nephritis with VIB4920 in addition to standard therapy is more effective than treating lupus nephritis with standard therapy alone.
Category:
Autoimmune Disease
|
Specific Category:
Lupus Nephritis
|
Status:
Enrollment
Learn more:
(
ITN090ST
|
ATTAIN
)
Principal Investigator:
Flavio Vincenti | University of California San Francisco | San Francisco, CA
Rajalingam Raja | University of California San Francisco | San Francisco, CA
The goal of ATTAIN is to study whether using two drugs, daratumumab and belatacept, together can lower the number of plasma cells in “highly sensitized” people on the kidney transplant waiting list.
Category:
Transplantation
|
Specific Category:
Kidney Transplantation
|
Status:
Follow-up
Learn more:
No items found.
